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Effects of atrial natriuretic factor in rats with experimental high-output
heart failure. The effects of atrial natriuretic factor (AN F) were evalu-
ated in rats with chronic aorto-caval (A-V) fistula. In this experimental
model of high-output heart failure, the animals display elevated atrial
pressure and systemic vasodilation, but avidly retain sodium. Experi-
ments were performed on Munich-Wistar rats, 8 to 14 days after
placement of an infrarenal surgical anastomosis (side-to-side, 0.9 0.2
mm) and on sham operated controls. Infusion of synthetic ANF (3-28)
intravenously (5 jg/kg prime; 0.17 jgIkg mm) resulted in increases in
urine flow (V) and fractional sodium excretion (FENa) and decreases in
blood pressure (BP) that were significantly attenuated in rats with A-V
fistula compared to controls. To control for the lower baseline BP that
was present in rats with A-V fistula, a second series of studies was
performed in which renal perfusion pressure was reduced in normal rats
to 110 mm Hg with a servocontrolled pneumatic cuff. ANF infusion to
this group led to significant increases in glomerular filtration rate (GFR),
V and FENa that were greater than those seen in rats with A-V fistula
(FENa = 2.7 0.3% vs. 0.48 0.12%, P <0.05). Thus, the moderately
reduced BP in rats with A-V fistula did not account for the blunted
response to ANF. To investigate whether the renal sensitivity to ANF
is altered in this model, an additional series of experiments were
performed in which ANF was infused over a range of doses (0.08 to 2.5
jg/kg'min) to both groups of rats. The changes in BP, GFR, V and
FENa following the incremental doses of ANF were significantly
attenuated in rats with A-V fistula. Indeed, the maximum natriuresis in
rats with A-V fistula was significantly lower in rats with A-V fistula
compared to controls (FENa = 2.1 0.7% vs. 5.0 0.5%, P < 0.05).
These data indicate that rats with A-V fistula have a diminished
sensitivity to ANF infusion. The blunted natriuretic response to ANF
may contribute to the renal retention of sodium in this experimental
model of heart failure.
Recent investigations have established that mammalian atria
synthesize and release a vasoactive and natriuretic peptide
termed, atrial natriuretic factor (ANF) L!—4]. This newly iden-
tified hormone is released during expansion of the extracellular
volume 5—8], presumably as a consequence of an increase in
atrial pressure and distension of the atria [9, 10]. Exogenous
infusion of ANF results in an increase in glomerular filtration
rate, sodium and water excretion and inhibition of the renin-
angiotensin-aldosterone system, despite a reduction in arterial
pressure 11, 12].
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Congestive heart failure is a syndrome characterized by
increased atrial pressures, decreased arterial pressure, avid
sodium retention with edema formation and activation of the
renin-angiotensin-aldosterone system L!3, 14]. Although initial
reports suggested that cardiac failure may be associated with a
deficiency of ANF 115, 161, more recent studies have clearly
established that circulating concentrations of the atrial peptide
are elevated in heart failure 17—22].
Studies in animals with experimental heart failure have
reported that the renal natriuretic response to exogenous ad-
ministration of ANF was markedly attenuated [23, 241. The
reduced excretion of sodium occurred in the presence of an
intact effect of ANF to increase the glomerular filtration rate
and to decrease arterial pressure. However, while these previ-
ous studies have provided insight into the renal and vasoactive
responses to ANF in heart failure, the experimental model that
was used may not have appropriately simulated the clinical
syndrome of congestive heart failure. The earlier investigations
were performed in low output states produced by thoracic caval
constriction in which cardiac filling pressures are decreased
rather than increased. Thus, circulating levels of ANF were
probably low, in contrast to the elevated levels characteristic of
the clinical syndrome.
The present study was therefore performed to evaluate the
effects of ANF in rats with chronic aorto-caval fistula. In this
experimental model of heart failure, central venous pressures
and circulating levels of ANF are elevated 25], yet the animals
avidly retain sodium leading to the formation of ascites and
peripheral edema [13, 26—28].
Methods
Studies were performed on Munich-Wistar rats (Haifa strain)
weighing 200 to 250 g. The animals were anesthetized with
sodium pentobarbital (35 mg/kg), and a surgical anastomosis
was placed between the abdominal aorta and inferior vena cava
distal to the origin of the renal arteries (side-to-side, 0.9 0.2
mm) according to the method described by Stumpe et al [29j.
An additional matched group of animals underwent sham oper-
ation. In this group, the aorta and vena cava were dissected
from the surrounding tissue and clamped for 5 to 10 minutes
without formation of a fistula. The animals were then placed in
individual metabolic cages and were maintained on standard rat
chow diet and tap water. To document some of the cardio-renal
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and endocrine changes that were induced by placement of the
A-V fistula, heart weight and plasma renin activity were deter-
mined in several animals, seven days following the operation.
Eight to fourteen days following the operation the rats were
anesthetized with an intraperitoneal injection of mactin (100
mg/kg; BYK Guldens, Konstanz, FRG) and prepared for clear-
ance experiments. The animals were placed on a temperature-
regulated table and body temperature was monitored with a
rectal probe. A tracheostomy was performed to clear the
airway. Polyethylene catheters were inserted in the jugular vein
for infusions, in the carotid artery for blood pressure measure-
ment and periodic blood sampling, and in the bladder for urine
collections.
A solution containing 2% inulin in normal saline was infused
intravenously at a rate equal to 1.5% of the body weight per
hour. Following an equilibration period of 60 to 80 minutes, one
of the three protocols described below was performed.
Series I: Renal and systemic response to ANF infusion
In this series the effects of a single dose infusion of atrial
natriuretic factor was evaluated in seven rats with aorto-caval
(A-V) fistula and in six sham-operated control rats. Two base-
line clearance periods of 20 minutes each were obtained. Urine
was collected into tared vials under mineral oil, and blood
samples were withdrawn into heparinized syringes at the mid-
point of each clearance period. Following these control collec-
tions, synthetic atrial natriuretic factor (26 amino acid, 3-28,
Peninsula Labs) was administered intravenously as a bolus (5
sag/kg) and followed by a sustained infusion (0.17 pg/kg . mm).
Urinary losses of sodium and volume were replaced with
isotonic saline. Thirty minutes after the initiation of the ANF
infusion, two clearance periods were obtained. At this point the
infusion of ANF was stopped and after thirty minutes two
additional urine collections were obtained (recovery phase). In
separate groups of rats with A-V fistula (N = 18) and sham
operated controls (N = 8) measurements were made of baseline
circulating ANF levels. These groups were not infused with
synthetic ANF.
Series 2: Dose response protocol
This series of studies was performed to evaluate the response
of rats with A-V fistula (N = 6) and sham operated controls (N
= 6) to increasing doses of ANF. Following two, 30-minute
control clearance periods, ANF was administered in incremen-
tal doses from 5 to 150 pg/kg as a bolus and continued with a
sustained infusion of the same dose for sixty minutes. Urine
collections were started after the peptide had been infused for
thirty minutes. In preliminary studies, the maximal natriuretic
and hemodynamic effects of ANF in normal rats were observed
with doses between 15 and 50 j.gJkg. Therefore, the very high
dose of 150 pg/kg was not given to the sham-operated control
group in this study.
Series 3: Response to ANF in normal rats during control of
renal peifusion pressure
This series of experiments were performed in normal rats to
assess the effects of ANF under conditions where renal perfu-
sion pressure was lowered to the levels seen in rats with A-V
fistula. The protocol was identical to series I with the exception
Table 1. Selected cardio-renal and endocrine parameters in sham
operated rats and in rats with A-V fistula
Sham control A-V fistula P
Heart weight g 0.84 0.05 1.04 0.05 <0.05
Heart weight ratio %
Body weight
0.32 0.02 0.46 0.02 <0.05
Central venous 4.5 1.6 16.4 3.9 <0.05
pressure mm Hg
Urinary sodium 1615 161 648 158 <0.05
excretion
1uEq/24 hr
Plasma renin activity 4.5 0.7 21.2 4.8 <0.05
ng Al/mi hr
Values are means sE for 7 control rats and 13 rats with A-V fistula.
Data for urinary sodium excretion were obtained at day 5 following
placement of the A-V fistula, whereas other values were obtained at day
7.
that, after an initial control clearance period of 30 minutes,
renal perfusion pressure was reduced to 110 mm Hg with an
inflatable silastic cuff placed on the aorta above the renal
arteries. The cuff was connected to an electronic servocontroll-
ing system that precisely maintained renal perfusion pressure at
that level for the duration of the experiment.
Inulin concentrations in plasma and urine were measured by
the anthrone method. Sodium and potassium concentrations
were measured by flame photometry. Plasma renin activity was
measured at pH 6.0 using a commercially available kit (New
England Nuclear, Boston, Massachusetts, USA). Concentra-
tions of immunoreactive ANF were measured in extracted
plasma by a sensitive radioimmunoassay previously described
t171. Briefly, samples were extracted on Sep-Pak, C-18 car-
tridges and dried in a vacuum. The samples were reconstituted
for radioimmunoassay, the recovery being greater than 80%.
The antibody and labelled peptide were purchased from Penin-
sula Labs (CA). The intraassay and interassay variabilities were
6% and 9%, respectively. The sensitivity of the assay is 3 pg/mI.
Statistical analysis
The data are presented as means SEM. Statistical compar-
isons between groups were made with analysis of variance for
repeated measures, and Student t-test for unpaired data. Com-
parisons within groups were made with paired t-test. A P valve
of 0.05 or less was considered to represent a significant differ-
ence.
Results
The placement of a chronic A-V fistula in rats resulted in
several expected effects, such as atrial hypertrophy and
tachypnea. The liver was enlarged and, in most rats, was
accompanied with ascites. Quantitative changes in several
cardio-renal and endocrine parameters are given in Table 1.
Most notably, heart weight, central venous pressure and plasma
renin activity were elevated in rats with A-V fistula compared to
controls. This was associated with diminished urinary excretion
of sodium. These data indicate that the experimental model of
A-V fistula in rats resembles the clinical syndrome of conges-
tive heart failure.
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Control ANF Recovery
Sham-operated (N =
MAP mm Hg
GFR ml/min
VpJ/min
UNaV
6)
143 4
1.7 0.3
19.9 4.8
1.0 0.2
120 4
2.2 0.3a
82.6 12.3
17.2 2.7
137 5b
1.9 0.2
7.6
6.2 09b
E
p.Eq/min
FENa %
UKV
p.Eq/min
A-V fistula (N = 7)
MAPmmHg
0.39 0.08
1.79 0.16
114±6
5.47 o.81
2.44 0.19a
105±5a
2.27 069b
1.02 011b
107±5
u
GFR ml/min
V p.1/mm
UNV p.Eq/min
FENa %
UKV p.Eq/min
1.4 0.3
6.9 2.6
0.16 0.04
0.09 0.03
0.79 0.37
1.6 0.3
12.8 2.8a
1.19 0.4a
0.48 0.12
1.70 0.43a
1.2 0.2
6.8 17b
0.91 0.21
0.61 0.22
0.87 028b
Values are means SE.Abbreviationsare: MAP, mean arterial blood
pressure; GFR, glomerular filtration rate; V. urine flow rate; UNaV,
absolute rate of sodium excretion; FENa, percentage of filtered sodium
excreted; UkV, absolute rate of potassium excretion.
a P 0.05 compared to control values
b p 0.05 compared to ANF administration data
Renal and systemic response to ANF infusion
The results of this series are Summarized in Table 2. Admin-
istration of ANF to sham operated animals significantly de-
creased mean arterial blood pressure, and significantly in-
creased the glomerular filtration rate. Urine flow and absolute
and fractional excretion of sodium and potassium rose signifi-
cantly. These changes returned towards control levels upon
cessation of ANF infusion.
In rats with A-V fistula, baseline systemic blood pressure was
20% lower than in sham controls, but the glomerular filtration
rate did not differ significantly and was maintained. However,
as indicated earlier in Table 1, central venous pressure in rats
with A-V fistula was significantly greater than in control rats.
This was associated with significantly higher circulating levels
of immunoreactive ANF in rats with A-V fistula compared to
sham-operated control rats (Fig. 1). As expected, the initial
urine flow and excretion of sodium and potassium were signif-
icantly lower in the experimental group compared to the control
group.
Infusion of ANF lead to significant decreases in mean arterial
blood pressure and to significant increases in urine flow and
absolute excretion of sodium and potassium. However, the
changes were markedly attenuated in rats with A-V fistula
compared to the sham-operated control group. Indeed, the
fractional excretion of sodium during infusion of ANF did not
exceed 1%, Interestingly, there were no significant changes in
the glomerular filtration rate during ANF infusion in the exper-
imental group. Thus, the natriuresis, diuresis, and vasodilation
accompanying the administration of a single dose of ANF were
significantly blunted in rats with A-V fistula. To examine
whether the attenuated response to ANF infusion reflected a
change in sensitivity to ANF, a second series of studies were
performed in which the response to increasing doses of ANF
was evaluated in control rats and in rats with A-V fistula,
ANF dose
p.g/kghr 0 5 IS 50
MAP 151 6 131 9' 95 5a.b 83 4','
mm
Hg
GFR 1.91 0.24 2.78 0.45a 3.14 0.51a 3.02 0.62
ml/min
V p.1/mm
UNaV
p.Eq/min
FENa %
15.0
2.0
0.71
4.8
0.6
0.23
79.9 25.Oa11.4 33
3.04 0.83a
106.2 18.3a
21.4 33a,h
5.0 o.52"
92.0 17.4
16.7 2.9
4.20 0.70
Dose response protocol
Data regarding the response of sham-operated rats to increas-
ing doses of ANF are given in Table 3. Administration of ANE
lead to dose dependent decreases in mean arterial blood pres-
sure and to increases in the glomerular filtration rate. Urine flow
and absolute, as well as fractional, excretion of sodium rose
progressively. With the exception of the effect of ANF on
systemic blood pressure, a maximal response in these parame-
ters was obtained in most animals at a dose ranging between 5
and 15 jig/kg hr. Submaximal responses were seen at higher
doses of ANF, most likely as a consequence of the further
decline in blood pressure.
The results in rats with A-V fistula appear in Table 4.
Increasing doses of ANF resulted in progressive decreases in
mean arterial blood pressure and steady increases in urine flow
and sodium excretion. The slight increments in the glomerular
filtration rate did not attain statistical significance. In an attempt
to reach a maximal response, a dose of 150 gIkg hr was given
Table 2. Renal and systemic effects of atrial natriuretic factor in
sham operated rats and rats with A-V fistula
1000
500
100
50
10
Fig. 1. Plasma concentrations of immunoreactive atrial natriuretic
factor (ANF) in rats with A-Vfistula and in s/lam operated controls.
Table 3. Renal and systemic effects of increasing doses of atrial
natriuretic factor in sham operated rats
Sham-control A-V fistula
Values and means SE for six animals. Abbreviations are given in
Table 2.
a Statistically different (P 0.05) compared to first period where no
ANF was administered
b P 0.05 compared to previous dose of ANF
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Table 4. Rena! and systemic effects of increasing doses of atria! natriuretic factor in rats with A-V fistula
ANF dose gI
kghr 0 5 IS SO ISO
MAPmrnHg 117±6 113 106±3u 98± 4a.b 994
GFR ,nllmin 1.14 0.12 1.15 0.14 1.32 0.18 1.55 0.48 1.3! 0.08
VplImin
UNflV pEqimin
FENa %
8.1 3.2
0.22 0.10
0.12 0.06
13.5
0.9!
0.48
4.5
0.32
0.12
27.5 9.2a
3.1 12.b
1.41 052a.b
32.2
4.7
1.47
16.2a2.
0.76a
19.4 6.6a
3.9 i.s'
2.05 0.68a
Values are means SE for six animals. Abbreviations are given in Table 2.
P 0.05 compared to first period where no ANF was administeredb P < 0.05 compared to previous dose of ANF
4
3
2
5 15
E
U-0
0 5 15 50 150
ANF dose, pg/kg hr
Fig. 2. Effects of increasing doses of ANF on gkimerular filtration rate(GFR) in sham control rats (0) and rats with A-Vfistula (I).
to this group. However, during infusion of this dose there were
no further changes in blood pressure. Indeed, with the excep-
tion of the fractional excretion of sodium, other parameters
actually declined.
The responses of both sham operated rats and rats with A-V
fistula to increasing doses of ANF are compared in Figures 2
and 3. The glomerular filtration rate (Fig. 2) and, the fractional
excretion of sodium (Fig. 3) are plotted for each dose of ANF.
In this series, the baseline values for the glomerular filtration
rate and fractional excretion of sodium were significantly lower
in rats with A-V fistula compared to sham operated controls.
Furthermore, the increases in both parameters following ANF
administration were significantfy attenuated in rats with A-V
fistula. Indeed, there was no significant increase in the glomer-
ular filtration rate and the fractional excretion of sodium, even
at the highest dose of ANF, was only 291c—a significantly lower
value than in control rats. This apparent "shift to the right" of
the dose response curve suggests either that rats with A-V
fistula have diminished sensitivity to ANF or that perhaps the
lower baseline systemic blood pressure altered the hemody-
namic and, consequently, the natriuretic response to ANF. To
further examine this issue, the next series was performed
wherein renal perfusion pressure was lowered in normal rats to
the level seen in rats with A-V fistula.
Response to ANF in normal rats during control ofrenal
perfusion pressure
The results of this series of experiments are shown in Figure
4. Renal perfusion pressure in normal rats was lowered from
6
S
4
wU-
2
0 50 150
ANF dose, pg/kg. hr
Fig. 3. Effects of increasing doses of ANF on fractional excretion of
sodium (FENU) in sham control rats (0) and rats with A-Vfistula (I).
134 mm Hg to 110 mm Hg, and maintained at that level
throughout the experiment. Administration of ANF lead to
significant increases in glomerular filtration rate (from 1.01
0.11 to 1.38 0.29 mI/mm, P < 0.05), urine flow (from 9 2 to
33 3 p1/mm, P < 0.05) and fractional excretion of sodium
(from 0.5 0.2 to 2.7 0.3%, P < 0.05). The results
demonstrate that a significant natriuresis and diuresis can occur
in an animal with moderately-reduced renal perfusion pressure.
More importantly, these data indicate that the blunted natriure-
sis and diuresis that occurred in response to ANF in rats with
A-V fistula is not a direct result of the lower renal perfusion
pressure present in those animals.
Discussion
The present study demonstrates that rats with A-V fistula, an
experimental model of high-output heart failure, display a
markedly attenuated response to administration of synthetic
atrial natriuretic factor compared to sham-operated control
rats. This conclusion is based on the following findings: First,
the diuretic and natriuretic effects of ANF were significantly
lower in rats with A-V fistula compared to sham operated rats.
In addition, the dose response curve of ANF-induced natriure-
sis was shifted to the right in rats with A-V fistula, suggesting a
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Pressure control
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>10 • I _____
Initial Basal ANF Recovery
Fig. 4. Effects of ANF in normal rats during control of renal perfusion
pressure (RPP) on glomerular filtration rate (GFR), urine flow (V) and
fractional excretion of sodium (FEN).
decreased sensitivity and diminished responsiveness of the
kidney to the natriuretic effects of the peptide. Second, whereas
in sham operated rats ANF administration resulted in a sub-
stantial elevation in the glomerular filtration rate, such an effect
was not observed in animals with A-V fistula, even with 10 to 30
times higher doses of ANF. Third, the decrement in mean
arterial blood pressure during ANF infusion was smaller in rats
with A-V fistula, suggesting an impaired vasorelaxant effect of
the peptide in this group. Thus, three major effects of atrial
natriuretic factor were attentuated in this experimental model of
high-output heart failure.
The results of this study are consistent with previous reports
regarding the effects of ANF on sodium excretion in other
experimental models of heart failure. In both conscious [23] and
anesthetized dogs with low-output heart failure [24], the natri-
uretic response to synthetic atrial peptide was attenuated com-
pared to normal dogs. However, in contrast to the present
findings, ANF induced similar increases in the glomerular
filtration rate and decreases in blood pressure in controls and in
animals with heart failure. This discrepancy may highlight a
fundamental difference between the two experimental models
of heart failure. The model of chronic A-V fistula used in the
present study represents a state of high atrial pressures and
elevated plasma levels of ANF, similar to the clinical syndrome
of congestive heart failure. It is possible that the genera'ized
resistance to the effects of ANF, observed in this model, relates
to the high circulating levels of endogenous atrial peptides (Fig.
1). The presence of chronically elevated levels of ANF may
have lead to receptor "down-regulation" and, consequently, to
decreased end-organ responsiveness. Indeed, "down-regu-
lation" of binding sites has been recently reported by Schiffrin
to occur in platelets of patients with congestive heart failure
[30]. The high circulating levels of ANF may explain the finding
of a lower baseline blood pressure in rats with A-V fistula and
the minimal decrease in blood pressure following infusion of
increasing doses of the peptide to these animals. On the other
hand, it would not explain the lower baseline glomerular
filtration rate and sodium excretion also present in these ani-
mals.
It is likely that additional mechanisms contribute to the
blunted natriuretic response to ANF in heart failure. Freeman,
Davis and Van suggested that the natriuretic response to ANF
infusion is dependent on the pre-existing status of the renal
tubules to reabsorb sodium [23]. In experimental models of
heart failure, there are several factors that may promote avid
sodium reabsorption and lead to the very low basal excretion of
sodium. In particular, activation of the renin-angiotensin-aldo-
sterone system and increases in renal sympathetic nerve activ-
ity are known to occur in heart failure [13, 14, 31], and may
enhance the renal retention of sodium and overcome the
natriuretic effects of ANF. Indeed, we have found elevated
plasma renin activity in rats with A-V fistula compared to
controls (Table 1). Clearly, the role of these systems in modu-
lating the effects of ANF, particularly in states of sodium
retention, needs to be carefully investigated.
Of interest are the findings regarding the effect of ANF in
normal rats during control of renal perfusion pressure. The
purpose of that series was to determine whether the lower renal
perfusion pressure (110 mm Hg), that was present in rats with
A-V fistula, contributed to the attenuated natriuretic response
to ANF infusion in that group. The data demonstrate that a
significant natriuresis and diuresis occurred in normal rats when
renal perfusion pressure was moderately reduced to 110 mm
Hg. Based on that finding, it was concluded that the blunted
natriuretic response to ANF in rats with A-V fistula cannot be
due solely to the lower renal perfusion pressure. However, the
fact that the magnitude of the natriuresis at a perfusion pressure
of 110 mm Hg (FENa = 2.7 3%) was less than was observed
in normal rats at renal perfusion pressures of 134 mm Hg (FENa
= 5.5 0.8%) indicates that the level of renal perfusion
pressure is an important factor in establishing the magnitude of
the natriuretic response to ANF. Thus, these data provide
further evidence for an important relationship between intrare-
nal pressures and ANF-induced natriuresis.
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